In the latest trading session, Lantheus Holdings (LNTH) closed at $77.67, marking a +1.17% move from the previous day. This change outpaced the S&P 500's 0.2% loss on the day. Meanwhile, the Dow lost 0.14%, and the Nasdaq, a tech-heavy index, lost 0.12%.Prior to today's trading, shares of the diagnostic imaging company had lost 3.4% over the past month. This has lagged the Medical sector's loss of 0.3% and the S&P 500's loss of 3.29% in that time.Investors will be hoping for strength from Lantheus Holdings as it approaches its next earnings release. In that report, analysts expect Lantheus Holdings to post earnings of $0.84 per share. This would mark year-over-year growth of 950%. Our most recent consensus estimate is calling for quarterly revenue of $228.52 million, up 123.88% from the year-ago period.Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of $3.57 per share and revenue of $898 million. These totals would mark changes of +628.57% and +111.19%, respectively, from last year.Investors should also note any recent changes to analyst estimates for Lantheus Holdings. These recent revisions tend to reflect the evolving nature of short-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. Lantheus Holdings is currently sporting a Zacks Rank of #3 (Hold).Valuation is also important, so investors should note that Lantheus Holdings has a Forward P/E ratio of 21.52 right now. This valuation marks a premium compared to its industry's average Forward P/E of 17.33.The Medical - Products industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 168, which puts it in the bottom 34% of all 250+ industries.The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions. Just Released: Free Report Reveals Little-Known Strategies to Help Profit from the $30 Trillion Metaverse Boom It's undeniable. The metaverse is gaining steam every day. Just follow the money. Google. Microsoft. Adobe. Nike. Facebook even rebranded itself as Meta because Mark Zuckerberg believes the metaverse is the next iteration of the internet. The inevitable result? Many investors will get rich as the metaverse evolves. What do they know that you don't? They’re aware of the companies best poised to grow as the metaverse does. And in a new FREE report, Zacks is revealing those stocks to you. This week, you can download, The Metaverse - What is it? And How to Profit with These 5 Pioneering Stocks. It reveals specific stocks set to skyrocket as this emerging technology develops and expands. Don't miss your chance to access it for free with no obligation.>>Show me how I could profit from the metaverse!Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Lantheus Holdings, Inc. (LNTH): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research